Alliance Creates Alternative to Maximize the Strengths of Each Organizations for Affected person Profit
Los Angeles, Calif. and Larkspur, Calif., January 9, 2024 – The Pancreatic Most cancers Motion Community (PanCAN), a number one affected person advocacy group devoted to combating the world’s hardest most cancers, in collaboration with the World Coalition for Adaptive Analysis (GCAR), right this moment introduced a strategic alliance to leverage options from Precision Promise — a PanCAN-sponsored, grasp protocol medical trial platform to check a number of regimens in metastatic pancreatic most cancers — to launch the subsequent part of this groundbreaking effort, a brand new grasp protocol for pancreatic most cancers sponsored by GCAR. This effort goals to proceed to speed up analysis for brand new remedy choices in pancreatic most cancers, the third main reason behind cancer-related deaths in the US.
“PanCAN has made a strategic resolution to collaborate with GCAR and benefit from the strengths of each organizations to pursue the long run sustainability of a brand new pancreatic most cancers medical trial platform for sufferers. PanCAN will proceed to deal with and observe sufferers at the moment enrolled in Precision Promise till the examine’s completion and GCAR will launch a subsequent technology platform trial with PanCAN because the affected person advocacy companion,” mentioned Julie Fleshman, JD, MBA, President and CEO, PanCAN. “We’re enthusiastic about GCAR’s funding in pancreatic most cancers and imagine that GCAR’s spectacular monitor report of innovating, operationalizing, and implementing the modernization of recent medical trial designs will drive and speed up progress for sufferers with pancreatic most cancers.”
The connection between PanCAN and GCAR spans a few years, as GCAR’s CEO, Dr. Meredith Buxton, performed a key position in crafting the unique Precision Promise protocol. The alliance between PanCAN and GCAR represents a dynamic synergy, harnessing the strengths of each organizations to speed up pancreatic most cancers analysis and produce new therapies to sufferers.
“GCAR is happy to collaborate with PanCAN to launch this revolutionary and groundbreaking effort, persevering with to work with the clinicians, affected person neighborhood and business to maneuver ahead the imaginative and prescient to enhance remedy choices for sufferers,” mentioned Dr. Meredith Buxton, CEO & President, GCAR. “We’re delighted to take the baton from PanCAN and thank them for his or her excellent work on Precision Promise, an unprecedented effort to check and approve new therapies for sufferers with metastatic pancreatic most cancers.”
This new trial will construct upon the precious insights gained by PanCAN thus far and enlists GCAR’s intensive expertise in conducting patient-centric grasp protocols and adaptive platform trials. PanCAN’s unparalleled illness experience, relationships with the pancreatic most cancers neighborhood, and PanCAN’s Affected person Providers program will proceed to be pivotal to the brand new examine and make sure that sufferers perceive their remedy choices. The objectives of the alliance are elevated effectivity and scalability by way of streamlined operations and the potential for web site growth, broader entry to various affected person populations, and better capacity to draw pharmaceutical and biotech companions. Bringing the strengths of each organizations collectively on this manner supplies new alternatives for innovation, development, and influence, and most significantly the development of recent therapies for sufferers with pancreatic most cancers.
“I’m grateful to PanCAN for his or her management as the primary affected person advocacy group to develop, lead and sponsor an adaptive medical trial platform to drive the event of recent, more practical therapies for pancreatic most cancers sufferers,” mentioned Diane Simeone, MD, Director of Pancreatic Most cancers Heart at NYU Langone Well being and chair of the Precision Promise Steering Committee. “The Precision Promise investigators are excited to collaborate with GCAR, together with PanCAN because the affected person advocacy companion, as we transition to this subsequent part of development to additional develop medical trial choices for sufferers.”
Concerning the Pancreatic Most cancers Motion NetworkThe Pancreatic Most cancers Motion Community (PanCAN) leads the way in which in accelerating essential progress for pancreatic most cancers sufferers. PanCAN takes daring motion by funding life-saving analysis, offering personalised affected person providers and making a neighborhood of supporters and volunteers who will cease at nothing to create a world during which all pancreatic most cancers sufferers will thrive. For 18 years in a row, PanCAN has earned a 4-Star Score from Charity Navigator – the very best ranking a company can obtain. This ranking designates PanCAN as an official “Give with Confidence” charity, indicating robust monetary well being, ongoing accountability and transparency.
About World Coalition for Adaptive ResearchThe World Coalition for Adaptive Analysis (GCAR) unites physicians, medical researchers, advocacy and philanthropic organizations, biotech/pharma, well being authorities, and different key stakeholders in healthcare to expedite the invention and improvement of therapies for sufferers with uncommon and lethal ailments. As Sponsor of revolutionary trials, together with grasp protocols and adaptive platform trials, GCAR is devoted to the development of science by modernizing medical trials that assist extra environment friendly, less expensive drug improvement. Adaptive platform trials ship an unmatched accelerated time from discovery within the lab to implementation within the clinic leading to higher therapies and lives saved. To be taught extra about GCAR and its initiatives, go to gcaresearch.org.
# # #
For media inquiries, please contact:
Pancreatic Most cancers Motion NetworkJulie VasquezSenior Director, Public Relations310-697-9129jvasquez@pancan.org
World Coalition for Adaptive ResearchRachel Rosenstein-SissonSenior Director, CommunicationsRrosenstein.sisson@gcaresearch.org